Thrombopoietin Agonists in Patients With Idiopathic Thrombocytopenic Purpura

NCT06137105 | Not Yet Recruiting

• 1 other identifier: TPO in ITP
• Study Type: observational
• Target: 100
• Locations: 0 countries
• Sites: N/A

Brief Summary

1. 1.Assesement of response to Thrombopoietin receptor agonists (TPO-RAs) as treatment in Idiopathic thrombocytopenia purpura patients in Assiut University hospital.
2. 2.Explore side effects of Thrombopoietin receptor agonists in Idiopathic thrombocytopenia purpura .
3. 3.To study effect of thrombopoietin receptor agonists and Quality life in Idiopathic thrombocytopenia purpura patients.

Conditions

ITP - Immune Thrombocytopenia

Outcome Measures

Primary Outcomes (1)

• Assessment of response to treatment will be clinical and laboratory assessment

  Platelet count should be measured weekly until a stable platelet count that is associated with an absence of bleeding symptoms is achieved for 4 weeks without adjustment and then measured monthly thereafter.

  Baseline

Study Arms (2)

Group 1

Group I : Romiplostim and Eltrombopag

Drug: eltrombopag and romiplastim

Group 2

Group II : recived corticosteroid.

Drug: eltrombopag and romiplastim

Interventions

eltrombopag and romiplastim DRUG

Group I: eltrombopag and romiplastim Group II : recived corticosteroid.

Also known as: Corticosteroids

Group 1; Group 2

Eligibility Criteria

• Age: 18 Years - 75 Years
• Sex: all
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Patients presented with Idiopathic thrombocytopenic purpura ( ITP) at clinical Hematology units, Internal Medicine Department at Assiut University . Patients above age of 18 years.

You may qualify if:

• Patients presented with Idiopathic thrombocytopenic purpura (ITP)
• patients above age of 18 years.

You may not qualify if:

• patients below age of 18 years .

Sponsors & Collaborators

• Assiut University: lead
• Association for Training, Education, and Research in Hematology, Immunology, and Transplantation: collaborator

MeSH Terms

Conditions

Purpura, Thrombocytopenic, Idiopathic

Interventions

eltrombopag; Adrenal Cortex Hormones

Condition Hierarchy (Ancestors)

Purpura, Thrombocytopenic; Purpura; Blood Coagulation Disorders; Hematologic Diseases; Hemic and Lymphatic Diseases; Thrombotic Microangiopathies; Thrombocytopenia; Blood Platelet Disorders; Cytopenia; Hemorrhagic Disorders; Autoimmune Diseases; Immune System Diseases; Hemorrhage; Pathologic Processes; Pathological Conditions, Signs and Symptoms; Skin Manifestations; Signs and Symptoms

Intervention Hierarchy (Ancestors)

Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: A Study of Treatment with thrombopoietin agonists in patients with Idiopathic thrombocytopenic purpura

Study Record Dates

• First Submitted: November 5, 2023
• First Posted: November 18, 2023
• Study Start: December 1, 2023
• Primary Completion (Estimated): December 1, 2026
• Study Completion (Estimated): December 1, 2026
• Last Updated: November 18, 2023

Record last verified: 2023-11